Fox Chase Cancer Center News

Fox Chase Cancer Center to Hold Fourth Annual Cancer Epigenetics Symposium

PHILADELPHIA (March 1, 2024) — Fox Chase Cancer Center’s Cancer Epigenetics Institute will hold its fourth annual free hybrid Cancer Epigenetics Symposium at the Franklin Institute in Philadelphia on Thursday, March 7. The annual event brings research leaders together to explore the latest discoveries that will assist in bringing epigenetics from the lab to patients.
VIEW STORY

Fox Chase Study Finds That Non-Hispanic Black Patients With Locally Advanced Rectal Cancer Have Less Favorable Outcomes

PHILADELPHIA (February 29, 2024) — While sociodemographic, clinical, and pathological factors may affect racial and ethnic disparities in outcomes of patients with locally advanced rectal cancer, non-Hispanic Black patients consistently saw less favorable treatment outcomes independent of those factors, according to a study from researchers at Fox Chase Cancer Center published today.
VIEW STORY

Made With Love: Fox Chase Nurses Serve Valentine-Themed Dinners to Cancer Patients and Families

PHILADELPHIA (February 28, 2024) – With 65 guests and infinite kindness, members of the Nursing Professional Development Council and the Department of Nursing of Fox Chase Cancer Center hosted “That’s Amore!,” on Tuesday, February 13. This Valentine-themed dinner featured a host of Italian delights and brought together cancer patients and their families staying at Hope Lodge.
VIEW STORY

Psychological Distress Found as Both a Contributor to and Consequence of Cancer Treatment Delay

PHILADELPHIA (February 23, 2024) — Prior research has shown that delays in initiating cancer therapy are increasing, and these delays can lead to not only worse outcomes for patients, but also increased psychological distress. However, a new study published by researchers at Fox Chase Cancer Center has found that patients’ worry and fear can also contribute to their intentionally delaying the start of treatment.
VIEW STORY

Fox Chase Researcher Finds Genetic Differences in Rare Kidney Cancer Subtype That Could Lead to More Effective Treatment

PHILADELPHIA (February 22, 2024) — TFE3-rearranged renal cell carcinoma (rRCC) is a rare subtype of kidney cancer that can be misdiagnosed. This can affect treatment decisions and lead to patients receiving the wrong type of treatment. Now, a recently published study by scientists at Fox Chase Cancer Center identifies key genetic markers that can be used to distinguish rRCC from other cancers and also confirms which therapies are likely to be most effective. 
VIEW STORY

Fox Chase Researchers Find Oral Vancomycin Prevents C. Diff Infection in Stem Cell Transplant Recipients but Raises Risk of Gram-Negative Bacteremia

PHILADELPHIA (February 19, 2024) — Stem cell transplant recipients can reduce their risk of Clostridioides difficile (C. diff) infection by taking the oral antibiotic vancomycin preventively, according to research from Fox Chase Cancer Center presented at a scientific meeting. However, the study also shows that taking this antibiotic can increase these patients’ risk of gram-negative bacteremia.
VIEW STORY